PERRIGO CO PLC

Drug pipeline (86)

Asset	Stage	Revenue	Trials	Status
ACETAMINOPHEN	approved	—	78	approved
ACETAMINOPHEN AND IBUPROFEN	approved	—	86	approved
ACETAMINOPHEN, ASPIRIN AND CAFFEINE	approved	—	104	approved
ANTITUSSIVE	approved	—	2	approved
ATORVASTATIN CALCIUM	approved	—	0	—

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (7)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT01744106	phase3	completed	2012-11-01	2016-04-01	Perrigo Company	A Multicenter Study of Pseudoephedrine for the Temporary Relief of Nasal Congestion in Children With the Common Cold
NCT00802828	phase1	completed	2004-06-01	2004-06-01	Perrigo Company	Bioequivalence Study Between Two Oral Formulations of Famotidine Tablets Under Fasting Conditions
NCT00803192	phase1	completed	2004-06-01	2004-06-01	Perrigo Company	Bioequivalence Study Between Two Oral Formulations of Famotidine Tablets Under Fed Conditions
NCT00804440	phase1	completed	2004-01-01	2004-01-01	Perrigo Company	Bioequivalence Study Between Two Oral Formulations of Ibuprofen 800 mg Tablets Under Fasting Conditions
NCT00803946	phase1	completed	2003-11-01	2003-11-01	Perrigo Company	Bioequivalence Study Between Two Oral Formulations of Ibuprofen 800 mg Tablets Under Fed Conditions

FDA applications (147)

Application

Approved

Type

Applicant

Products

ANDA 216792

2025-10-07

ANDA

L PERRIGO CO

ANDA 214836

2023-02-28

ANDA

L PERRIGO CO

NDA 215712

2022-03-17

NDA

PERRIGO PHARMA INTERNATIONAL DAC

ANDA 214407

2022-02-01

ANDA

L PERRIGO CO

ANDA 208478

2020-06-23

ANDA

PERRIGO R AND D CO